JAZZ Robert Iannone sells $991K worth of shares
Mar 08, 2025, 5:32 AM
0.00%
What does JAZZ do
Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
Robert Iannone sold 7,080 shares of JAZZ on 7 March at $140.00 per share, worth a total of $991K. They now own 83,572 JAZZ shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.